Jakura

Jakura Therapeutics is a pre-clinical stage biotechnology company focused on developing next-generation Janus kinase (JAK) inhibitors for the treatment of autoimmune and inflammatory diseases. The company's primary focus is on creating highly selective small molecule inhibitors that target specific JAK isoforms to improve safety profiles and therapeutic efficacy compared to existing pan-JAK inhibitors. By leveraging advanced medicinal chemistry, Jakura aims to address significant unmet needs in dermatology, rheumatology, and gastroenterology. Their lead programs are currently undergoing optimization and early safety studies to support future IND filings.